The global anti-diabetic drugs market size was estimated to be USD 2.26 billion in 2023 and is expected to reach USD 4.35 billion by 2034 with a CAGR of 6.14% during the forecast period 2024-2034. The rising prevalence of diabetes, technological advancements, increased adoption in emerging markets, government initiatives, and rising healthcare expenditure will drive the market growth.
The rising prevalence of diabetes worldwide is the key driver of the anti-diabetic medications industry. The rising prevalence of type 1 and type 2 diabetes has contributed significantly to the need for anti-diabetic drugs. Pharmaceutical companies' ongoing research and development efforts result in releasing new and more effective anti-diabetic medications. As consumers and healthcare professionals seek better treatment alternatives, medication development advances help expand the market. For instance, Novo Nordisk A/S received FDA clearance for Ozempic (semaglutide) as a first-line therapy for type 2 diabetes in September 2023, cementing its GLP-1 supremacy.
By diabetes type, the type 2 diabetes segment accounted for the highest revenue-grossing segment in the global anti-diabetic drugs market in 2023 owing to the increasing prevalence of type 2 diabetes worldwide, a growing aging population, and a rising awareness of the importance of early diagnosis and effective management of the disease. For instance, in July 2023, Sanofi S.A. presented strong Phase 2b data for its SGLT2 inhibitor candidate Sotagliflozin, showing its potential for combined cardiovascular and renal benefits. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to the escalating research and development activities focusing on novel therapies, personalized medicine approaches, and innovative treatment modalities within the broader field of diabetes management.
By drug type, the biguanides (Metformin) segment accounted for the highest revenue-grossing segment in the global anti-diabetic drugs market in 2023 owing to the well-established efficacy, long-standing clinical use, and a favorable safety profile of biguanides, with Metformin being a widely prescribed and first-line medication for the treatment of type 2 diabetes. For instance, Eli Lilly and Company announced a strategic agreement with Boehringer Ingelheim in December 2023 to co-develop and market possible next-generation diabetes medicines other than DPP-4 inhibitors. Additionally, the sodium-glucose cotransporter 2 (SGLT2) Inhibitors segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of SGLT2 inhibitors' unique mechanism of action, which involves inhibiting glucose reabsorption in the renal tubules, leading to improved glycemic control.
By patient type, the adults segment accounted for the highest revenue-grossing segment in the global anti-diabetic drugs market in 2023 owing to the rising prevalence of diabetes in the adult population, as this demographic group represents the majority of diagnosed cases globally. For instance, in September 2023, Merck & Co., Inc. presented positive Phase 2 data for their experimental once-weekly oral SGLT2 inhibitor MK-6776, demonstrating the potential for enhanced convenience and adherence. Additionally, the geriatric segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing geriatric population, characterized by an increased prevalence of diabetes-related complications and the rising demand for specialized and tailored healthcare solutions for age-related co-morbidities.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global anti-diabetic drugs market in 2023 owing to the increased acuity of diabetes cases requiring inpatient care and the heightened availability of a wide range of anti-diabetic drugs within hospital pharmacy settings. For instance, Johnson & Johnson presented good Phase 3 data in October 2023 for their experimental oral SGLT2 inhibitor empagliflozin (a separate chemical from their commercialized Jardiance) in lowering cardiovascular risk in high-risk type 2 diabetic patients. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of digital platforms for healthcare services, the convenience of online purchasing, and a rising trend towards telemedicine and remote healthcare management.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of diabetes, and robust research and development activities in the pharmaceutical sector. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of diabetes, increasing awareness about diabetes management, and the expanding healthcare infrastructure in several countries within the Asia Pacific region. For instance, AstraZeneca PLC announced a strategic agreement with Dexcom in December 2023 to develop and market integrated diabetes care products combining GLP-1 agonists and CGM technologies.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
The rising prevalence of diabetes worldwide is the key driver of the anti-diabetic medications industry. The rising prevalence of type 1 and type 2 diabetes has contributed significantly to the need for anti-diabetic drugs. Pharmaceutical companies' ongoing research and development efforts result in releasing new and more effective anti-diabetic medications. As consumers and healthcare professionals seek better treatment alternatives, medication development advances help expand the market. For instance, Novo Nordisk A/S received FDA clearance for Ozempic (semaglutide) as a first-line therapy for type 2 diabetes in September 2023, cementing its GLP-1 supremacy.
By diabetes type, the type 2 diabetes segment accounted for the highest revenue-grossing segment in the global anti-diabetic drugs market in 2023 owing to the increasing prevalence of type 2 diabetes worldwide, a growing aging population, and a rising awareness of the importance of early diagnosis and effective management of the disease. For instance, in July 2023, Sanofi S.A. presented strong Phase 2b data for its SGLT2 inhibitor candidate Sotagliflozin, showing its potential for combined cardiovascular and renal benefits. Additionally, the other segment is predicted to grow at the fastest CAGR during the forecast period owing to the escalating research and development activities focusing on novel therapies, personalized medicine approaches, and innovative treatment modalities within the broader field of diabetes management.
By drug type, the biguanides (Metformin) segment accounted for the highest revenue-grossing segment in the global anti-diabetic drugs market in 2023 owing to the well-established efficacy, long-standing clinical use, and a favorable safety profile of biguanides, with Metformin being a widely prescribed and first-line medication for the treatment of type 2 diabetes. For instance, Eli Lilly and Company announced a strategic agreement with Boehringer Ingelheim in December 2023 to co-develop and market possible next-generation diabetes medicines other than DPP-4 inhibitors. Additionally, the sodium-glucose cotransporter 2 (SGLT2) Inhibitors segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of SGLT2 inhibitors' unique mechanism of action, which involves inhibiting glucose reabsorption in the renal tubules, leading to improved glycemic control.
By patient type, the adults segment accounted for the highest revenue-grossing segment in the global anti-diabetic drugs market in 2023 owing to the rising prevalence of diabetes in the adult population, as this demographic group represents the majority of diagnosed cases globally. For instance, in September 2023, Merck & Co., Inc. presented positive Phase 2 data for their experimental once-weekly oral SGLT2 inhibitor MK-6776, demonstrating the potential for enhanced convenience and adherence. Additionally, the geriatric segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing geriatric population, characterized by an increased prevalence of diabetes-related complications and the rising demand for specialized and tailored healthcare solutions for age-related co-morbidities.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global anti-diabetic drugs market in 2023 owing to the increased acuity of diabetes cases requiring inpatient care and the heightened availability of a wide range of anti-diabetic drugs within hospital pharmacy settings. For instance, Johnson & Johnson presented good Phase 3 data in October 2023 for their experimental oral SGLT2 inhibitor empagliflozin (a separate chemical from their commercialized Jardiance) in lowering cardiovascular risk in high-risk type 2 diabetic patients. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of digital platforms for healthcare services, the convenience of online purchasing, and a rising trend towards telemedicine and remote healthcare management.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of diabetes, and robust research and development activities in the pharmaceutical sector. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising incidence of diabetes, increasing awareness about diabetes management, and the expanding healthcare infrastructure in several countries within the Asia Pacific region. For instance, AstraZeneca PLC announced a strategic agreement with Dexcom in December 2023 to develop and market integrated diabetes care products combining GLP-1 agonists and CGM technologies.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Diabetes Type, Drug Type, Patient Type, End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Anti-diabetic Drugs Market Report 2023 - 2034
Anti-diabetic Drugs Market Analysis & Forecast by Diabetes Type 2023 - 2034 (Revenue USD Bn)
- Diabetes Type 1
- Diabetes Type 2
- Others
Anti-diabetic Drugs Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Bn)
- A-Glucosidase Inhibitors (Acarbose)
- Biguanides (Metformin)
- Dipeptidyl Peptidase IV (DPP-IV) Inhibitors (Sitagliptin)
- Meglitinides (Repaglinide)
- Sulfonylureas (Glimepiride)
- Thiazolidinediones (Pioglitazone)
- Others
Anti-diabetic Drugs Market Analysis & Forecast by Patient Type 2023 - 2034 (Revenue USD Bn)
- Adult
- Geriatric
- Pediatric
Anti-diabetic Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Retail Pharmacies/Drug Stores
- Online Pharmacies
Anti-diabetic Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Anti-diabetic Drugs Market: Diabetes Type Estimates & Trend Analysis
8. Anti-diabetic Drugs Market: Patient Type Estimates & Trend Analysis
9. Anti-diabetic Drugs Market: Patient Type Estimates & Trend Analysis
10. Anti-diabetic Drugs Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Anti-diabetic Drugs Market
13. Europe Global Anti-diabetic Drugs Market
14. Asia Pacific Global Anti-diabetic Drugs Market
15. Latin America Global Anti-diabetic Drugs Market
16. MEA Global Anti-diabetic Drugs Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Medtronic plc
- Boston Scientific Corporation
- Kimberly-Clark Corporation
- C.R. Bard Inc.
- Coloplast A/S
- Ethicon US Llc (a subsidiary of Johnson & Johnson)
- B. Braun Melsungen AG
- Teleflex Incorporated
- Hollister Incorporated
- ConvaTec Group plc
- Astora Women's Health
- ZSI Surgical Implants
- InControl Medical LLC
- Atlantic Therapeutics
- Becton
- Dickinson and Company.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.26 Billion |
| Forecasted Market Value ( USD | $ 4.35 Billion |
| Compound Annual Growth Rate | 6.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
